Table 2.
Incidence of myocarditis after COVID-19 vaccination based on data from voluntary vaccine adverse event reporting systems
| The Netherlandsa | United Kingdomb | Europec | United Statesd | ||||
|---|---|---|---|---|---|---|---|
| Sex | Male | Female | Male and female | Male and female | Male and female | ||
| Dose | First dose | Second dose | First dose | Second dose | First and second doses | At least one dose | First and second doses |
| Pfizer-BioNTech (Comirnaty) | 3.0 | 3.8 | 0.6 | 1.1 | 4.3 | 4.2 | 6.5 |
| Moderna (Spikevax) | 10.0 | 10.9 | 5.9 | 6.4 | 14.7 | 6.2 | 3.7 |
a Incidence per 1 million vaccine doses; results based on data from the Netherlands Pharmacovigilance Centre Lareb (until 19 October 2021) [29]
b Incidence per 1 million vaccine doses; results derived from website of the United Kingdom government (until 28 July 2021, accessed on 20 December 2021) [30]
c Incidence per 1 million vaccinated persons; results based on data from EudraVigilance (until 6 August 2021), calculated by Lane et al. [31]
d Incidence per 1 million vaccinated persons; results based on Vaccine Adverse Event Reporting System data (until 6 August 2021), calculated by Lane et al. [31]